{
    "nctId": "NCT00524810",
    "briefTitle": "Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer",
    "officialTitle": "A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 67,
    "primaryOutcomeMeasure": "Non-progression rate after 6 cycles",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* first metastatic chemo line\n* presence of measurable or bone lesion\n* at least one lesion outside the radiated areas\n* can have previously received hormonotherapy, chemotherapy in adjuvant phase, radiotherapy if older than 4 weeks\n\nExclusion Criteria:\n\n* only local tumoral progression\n* symptomatic cerebral metastasis\n* neuropathy \\> NCI-CTC 2\n* previous cancer within 10 years _ previous cancer within 10 years",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}